Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Aurora Cannabis Inc. ACB

Healthcare — Drug Manufacturers Specialty & Generic

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
249.63
Revenue
209.97
Net Income
(31.33)
Free Cash Flow
(36.10)
Net Debt
(95.56)
Current Ratio
5.36
Debt/Equity
0.03
P/E ratio
0.00
P/S ratio
1.14
P/B ratio
0.63
Past 5Y EPS Growth
67.71%
This Y EPS Growth
86.25%
Next Y EPS Growth
161.79%
Next 5Y EPS Growth
27.04%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2026 ‡‡‡‡‡
2025 ‡‡‡‡‡
2024 ‡‡‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 135.85 133.59 119.21 107.71
Receivables 33.66 30.52 32.27 29.68
Inventory 138.16 171.84 126.72 135.46
Other 1.60 0.16 1.44 2.27
316.24 343.77 287.68 284.19
2024 2025 2026 Q'26
Payables 43.41 52.90 36.62 41.05
ST’ Debt 38.82 15.46 — —
Other 4.16 1.21 1.72 1.80
92.38 79.68 48.44 53.04
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Sep Dec Mar Jun Year
’26 — — — 48.79
—
’26 65.60 67.56 28.01 70.87
232.05
’25 59.46 62.99 63.31 60.97
246.72
’24 47.27 47.31 49.92 —
200.36
’23 37.75 45.48 53.04 55.87
175.41
’22 47.75 48.08 39.82 39.23
174.88
’21 50.91 51.98 43.57 44.99
191.44
in millions of $

Operating Cash Flow

Jun Sep Dec Mar Year
’26 (3.21) — — —
—
’26 7.32 (29.30) 12.45 (0.25)
(9.78)
’25 6.12 (18.23) 20.91 2.70
11.50
’24 — (23.03) (3.41) (15.99)
(50.78)
’23 (8.36) (23.86) (43.82) —
(87.08)
’22 (86.78) (18.01) (17.09) (30.59)
(86.78)
’21 (164.38) (81.47) (51.16) (49.02)
(164.38)
in millions of $

Free Cash Flow

Jun Sep Dec Mar Year
’26 (7.12) — — —
—
’26 3.68 (33.37) 8.67 (4.28)
(25.30)
’25 3.28 (21.48) 17.85 (0.24)
(0.59)
’24 — (26.00) 1.12 (19.60)
(54.25)
’23 (9.77) (23.84) (35.21) —
(87.08)
’22 (96.71) (15.59) (26.22) (22.76)
(96.71)
’21 (190.79) (92.72) (58.20) (59.21)
(190.79)
in millions of $

EPS

Sep Dec Mar Jun Year
’26 — — — (0.05)
—
’26 (0.66) 0.02 (0.72) (0.20)
(1.55)
’25 (0.16) 0.41 (0.24) 0.10
0.03
’24 (0.10) (0.40) (0.30) —
(1.13)
’23 (1.30) (1.50) 1.00 (0.60)
(0.62)
’22 (0.50) (3.00) (37.30) (2.03)
(6.31)
’21 (6.90) (13.40) (6.70) (0.55)
(3.31)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.4
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 8.21 4.10 2.84 3.42 2.56 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.50 12.05 9.35 6.91 4.49 — — —
High Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,338 — 1,073 1,130 1,028 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.00 0.19 0.22 0.23 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 174.88 175.41 200.36 246.72 232.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.59% (27.59%) 48.64% 54.65% 42.62% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,359.07) (222.12) (44.18) 14.65 (40.91) — — —
EBT
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (777.14%) (126.63%) (22.05%) 5.94% (17.63%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,357.37) (199.50) (43.77) 11.33 (42.43) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 74.00 24.57 27.34 18.94 13.03 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.14 0.54 4.64 4.50 4.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.31) (0.62) (1.13) 0.03 (1.55) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.04) (0.27) (1.17) 0.21 (0.17) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.46) 0.00 (0.08) (0.22) (0.27) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.50) (0.27) (1.26) (0.01) (0.45) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.35 1.13 10.32 7.98 6.53 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.49 322.74 43.22 54.83 56.71 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 39.91 0.00 ‡‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.22 0.98 0.93 0.98 0.80 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.42 0.50 0.42 0.55 0.50 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.20 0.71 0.62 0.72 0.53 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.48) (0.82) (2.30) (302.77) (4.89) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (86.78) (87.08) (50.78) 11.50 (9.78) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.93) (9.12) (3.47) (12.09) (15.52) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (96.71) (87.08) (54.25) (0.59) (25.30) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 473.98 178.95 223.86 264.10 239.23 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 208.07 171.43 74.08 71.30 13.12 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (179.17) (54.89) (61.77) (62.30) (106.08) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 523.33 365.41 446.17 437.39 370.46 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (93.92%) (25.69%) (7.38%) 0.26% (16.82%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.21%) 0.00% (5.60%) 0.59% (7.98%) — — —
ROIC
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (128.39%) (44.89%) (11.98%) 0.37% (21.82%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Aurora Cannabis Inc. (ACB) embodies the cannabis industry’s boom-and-bust saga, surging post-Canada’s 2018 legalization before crashing amid overexpansion and losses, much like the dot-com era. Recent restructuring has yielded bright spots: revenue stabilizing around CAD 200 million with 7% CAGR projected to 2028, gross margins leaping to 49% in 2024 and 55% in 2025 via cost cuts and a medical cannabis pivot, and debt slashed 85% to leave the firm cash-rich. Employee efficiency has doubled revenue per head, signaling leaner operations in a commoditized market.

Yet profitability remains fragile, with net income swinging from CAD 11 million profits in 2025 forecasts to losses by 2026, razor-thin EBT margins at 6%, and high EV/FCF ratios flagging overvaluation risks. Cash flows have turned positive, but capex for EU expansion persists, while stock prices—down 98% from peaks—hover near lows with analyst targets implying 75% mean upside amid normalized valuations.

ACB’s disciplined turnaround tempts tactical buys, bolstered by regulatory tailwinds like Germany’s legalization, but U.S. rescheduling delays, competition, and EPS volatility demand caution. Fundamentals now tightly correlate with price, hinting at re-rating potential for patient investors if sustained profits materialize—echoing survivors who thrived post-hype.

Read full commentary →

Aurora Cannabis Inc. (ACB) Latest News

News by impact score

Fine-tune

16 Sep

4 , 7:05 AM
Aurora Cannabis acquires Safari Flower Company accretively and expects leading European performance to drive international growth from fiscal Q2 2027 onward. Accretive acquisition combined with European momentum supports major international expansion and revenue trajectory shift.

4 , 7:05 AM
Aurora Cannabis completes accretive acquisition of Safari Flower Company with strong European performance expected to drive international growth from fiscal Q2 2027 onward. Accretive acquisition and European results create major strategic push for international expansion and performance.

15 Sep

5 investorshub.advfn.com, 10:09 AM
Curaleaf urges Aurora Cannabis shareholders to tender shares to its takeover offer. Takeover offer by Curaleaf would fundamentally alter Aurora Cannabis ownership and trajectory if completed.

4 www.marketbeat.com, 1:30 PM
Curaleaf launches hostile takeover bid for Aurora Cannabis Inc. in move to consolidate cannabis sector assets. Hostile acquisition attempt by Curaleaf introduces major risk of ownership change and operational overhaul for Aurora.

4 , 7:30 AM
Curaleaf sent a letter to Aurora Cannabis Inc. shareholders outlining a strategic proposal that could lead to acquisition or major transaction affecting the company. Curaleaf letter signals possible acquisition attempt with significant implications for Aurora's market position and trajectory.

14 Sep

4 app.moby.co, 3:50 PM
Curaleaf seeks regulatory freeze on Aurora Cannabis stock sales during extended hostile takeover bid. Hostile bid with stock sales freeze request creates major risks to Aurora's control and valuation.

9 Sep

4 app.moby.co, 10:22 AM
Aurora Cannabis and Curaleaf continue mutual criticisms as Curaleaf's hostile takeover bid intensifies. Hostile takeover bid directly threatens Aurora's independence and could reshape its market position.

3 , 7:05 AM
Aurora Cannabis Inc. appoints a seasoned biopharmaceutical executive to lead commercial acceleration of its global medical cannabis business. Executive appointment targets commercial growth in medical cannabis and may moderately influence operational strategies.

8 Sep

3 , 9:33 AM
Curaleaf releases fact sheet countering misleading statements from Aurora Cannabis on industry matters. Public rebuttal from competitor risks short-term damage to Aurora's credibility and sentiment.

3 , 9:33 AM
Curaleaf releases fact sheet disputing statements from Aurora Cannabis Inc. Public dispute with Curaleaf risks damaging Aurora's credibility among investors and regulators.

2 Sep

4 , 4:14 PM
Aurora Cannabis board recommends rejecting Curaleaf bid. Rejection of Curaleaf takeover bid represents major strategic decision likely to affect Aurora Cannabis valuation and trajectory.

4 , 11:17 AM
Curaleaf reaffirms its offer to Aurora Cannabis shareholders as the best path to value creation in direct response to Aurora's circular. Reaffirmed takeover offer introduces major strategic shift that could determine Aurora's ownership and future trajectory.

4 , 7:59 AM
Aurora Cannabis urges shareholders to reject Curaleaf's takeover bid. Takeover bid rejection effort signals major strategic defense that could alter Aurora Cannabis independence and valuation trajectory.

4 , 7:05 AM
Aurora Cannabis urged shareholders to reject Curaleaf's hostile bid, calling it inadequate and warning it undervalues the company while endangering shareholder value and future growth. Hostile bid rejection introduces major uncertainty over ownership and valuation that can sharply move stock and strategic direction.

4 , 7:05 AM
Aurora Cannabis urges shareholders to reject Curaleaf's hostile bid as inadequate, undervaluing the company and risking future shareholder value and upside. Hostile takeover attempt and rejection signal major strategic shift with direct effects on Aurora ownership structure and valuation.

28 Aug

4 www.fool.com, 6:35 AM
Curaleaf launches hostile takeover bid for Aurora Cannabis Inc., prompting questions on whether ACB stock remains a buy amid potential acquisition. Hostile takeover bid by Curaleaf could fundamentally alter Aurora Cannabis's ownership and strategic direction.

24 Aug

4 stocktwits.com, 8:12 PM
Curaleaf rejects Aurora Cannabis's defense and reiterates its $4 premium takeover offer. Reiterated premium takeover offer raises likelihood of acquisition altering Aurora ownership and trajectory.

4 stocktwits.com, 8:38 AM
Aurora Cannabis disputes inaccuracies in Curaleaf’s takeover bid announcement as CEO claims business reaches pivotal inflection point. Takeover bid response and inflection point claim signal major strategic developments likely to shift company trajectory and investor views.

4 , 7:05 AM
Aurora Cannabis corrects inaccurate statements made in support of Curaleaf Holdings' hostile bid. Hostile bid defense directly influences company control, valuation, and investor outlook.

21 Aug

4 www.fool.com, 8:35 AM
Curaleaf launches hostile takeover bid for Aurora Cannabis, marking start of wider cannabis industry consolidation where two other stocks stand to gain most. Hostile takeover bid by Curaleaf directly threatens Aurora's independence and could force major strategic shifts or ownership change.

20 Aug

5 www.fool.com, 7:50 AM
Curaleaf launches hostile takeover attempt on Aurora Cannabis Inc., prompting questions on whether Curaleaf stock qualifies as a buy. Hostile takeover bid targets Aurora Cannabis and may fundamentally alter its ownership structure and market trajectory.

19 Aug

4 , 1:45 PM
Aurora Cannabis acquires Internode Pharma Limited and HAP Pharma Limited in an accretive deal that expands its global medical cannabis operations and UK distribution access. Accretive acquisition of two companies directly boosts Aurora's UK market reach and global growth strategy.

4 , 7:05 AM
Aurora Cannabis Inc. urges shareholders to take no action on Curaleaf Holdings, Inc.'s unsolicited takeover bid. Unsolicited takeover bid creates major strategic uncertainty for Aurora Cannabis ownership and direction.

18 Aug

5 , 8:00 AM
Curaleaf launches takeover bid for Aurora Cannabis, inviting ACB shareholders to tender shares to the offer. Takeover bid by Curaleaf targets full acquisition of Aurora Cannabis, which would end its independent operations and reshape its market trajectory.

4 , 11:59 AM
Curaleaf launches unsolicited takeover bid to buy Aurora Cannabis Inc. (ACB). Unsolicited takeover bid by Curaleaf signals major strategic development likely to reshape Aurora Cannabis ownership and market trajectory.

16 Aug

5 www.fool.com, 12:50 AM
Curaleaf proposes acquiring Aurora Cannabis for $272 million, sparking speculation that Canopy Growth may become the next marijuana sector takeover target. A $272 million acquisition bid from Curaleaf constitutes a transformative development capable of redefining Aurora Cannabis's ownership and market position.

13 Aug

4 app.moby.co, 3:01 PM
Curaleaf CEO defends hostile bid for Aurora Cannabis Inc. (ACB) as company pursues acquisition of the cannabis producer. Hostile takeover bid by Curaleaf creates major strategic challenge that could reshape Aurora Cannabis ownership and operations.

12 Aug

5 www.barchart.com, 2:08 PM
Curaleaf announces takeover bid for Aurora Cannabis Inc. (ACB). Curaleaf takeover bid has potential to fundamentally redefine Aurora Cannabis ownership and operations.

4 www.fool.com, 2:59 PM
Curaleaf weighs acquiring Aurora Cannabis Inc. to expand operations and market share in the cannabis sector. Potential acquisition by Curaleaf represents major strategic move that could significantly reshape Aurora Cannabis trajectory.

3 transcript www.fool.com, 11:13 AM
Aurora Cannabis (ACB) released its Q1 2027 earnings call transcript detailing financial results, operational updates and forward guidance. Quarterly earnings transcripts deliver financial metrics and outlook that can moderately shift near-term investor sentiment and stock performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us